PABAL

This brand name is authorized in Austria, Estonia, Finland, France, Ireland, Israel, Lithuania, Netherlands, Nigeria, Poland, Romania, South Africa, Turkey, UK.

Active ingredients

The drug PABAL contains one active pharmaceutical ingredient (API):

1	Carbetocin UNII 88TWF8015Y - CARBETOCIN
	Carbetocin selectively binds to oxytocin receptors in the smooth muscle of the uterus, stimulates rhythmic contractions of the uterus, increases the frequency of existing contractions, and raises the tone of the uterus musculature.
	Read more about Carbetocin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PABAL Solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H01BB03	Carbetocin	H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01B Posterior pituitary lobe hormones → H01BB Oxytocin and analogues
Discover more medicines within H01BB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1261796
FI	Lääkealan turvallisuus- ja kehittämiskeskus	129873
FR	Base de données publique des médicaments	62023123
GB	Medicines & Healthcare Products Regulatory Agency	355558
IL	מִשְׂרַד הַבְּרִיאוּת	8158
LT	Valstybinė vaistų kontrolės tarnyba	1076900
NG	Registered Drug Product Database	B4-9085
NL	Z-Index G-Standaard, PRK	128058
PL	Rejestru Produktów Leczniczych	100162320
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W61784001
TR	İlaç ve Tıbbi Cihaz Kurumu	8697621750449, 8697621790650
ZA	Health Products Regulatory Authority	42/19/0383